Brian Park, PharmD

Drug Information Specialist https://www.empr.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

News

Topical Antiviral Gel Looks Promising for Molluscum Contagiosum

Brian Park, PharmD

June 11, 2021

SB206 is an investigational nitric oxide-releasing topical gel that contains berdazimer sodium plus a hydrogel.

News

Epclusa Approved for Younger Patients With Chronic Hepatitis C

Brian Park, PharmD

June 11, 2021

The expanded approval was based on data from an open-label phase 2 trial that evaluated Epclusa in 41 patients 3 years to less than 6 years of age with chronic HCV infection.

News

RECELL System Approval Expanded to Pediatric Patients, Extensive Burn Wounds

Brian Park, PharmD

June 10, 2021

The pediatric approval was based on data from the RECELL Compassionate Use (IDE 15945) and Continued Access (IDE 13053) studies.

News

Moderna Requests EUA for COVID-19 Vaccine Use in Adolescents

Brian Park, PharmD

June 10, 2021

The submission is based on data from the phase 2/3 TeenCOVE study, which included over 3700 US adolescents aged 12 to less than 18 years.

News

Lymphoseek Approval Expanded to Pediatric Patients

Brian Park, PharmD

June 10, 2021

The approval was based on data from a phase 2 trial that assessed Lymphoseek in pediatric patients with melanoma, RMS, or other solid tumors.

Drugs in the Pipeline

Etrasimod Granted Orphan Drug Status for Eosinophilic Esophagitis

Brian Park, PharmD

June 9, 2021

Etrasimod is an investigational, next generation, once-daily, oral, highly selective sphingosine 1-phosphate receptor modulator.

News

FDA Accepts Resubmitted Zimhi NDA for Opioid Overdose Treatment

Brian Park, PharmD

June 9, 2021

The FDA has accepted for review the resubmitted NDA for Zimhi, a high-dose naloxone injection product candidate for the treatment of opioid overdose.

News

Trikafta Approval Expanded to Include Younger Cystic Fibrosis Patients

Brian Park, PharmD

June 9, 2021

The approval was based on data from a phase 3 study that evaluated Trikafta in 66 children 6 to 11 years of age with CF who were either homozygous for the F508del mutation or heterozygous for the F508del mutation and 1 minimal function mutation.